Participated · Series B · Feb 2017

Laminate Medical Technologies develops the VasQ, an external vascular support device implanted during AV fistula creation to reduce vein wall tension and regulate fistula geometry for dialysis patients. The VasQ already has CE approval and has been applied successfully in Germany and other European countries for hundreds of patients. The company has begun clinical trials at 16 leading U.S. hospitals as part of a push to obtain FDA approval and enter the American market. Laminate operates an R&D center in Ramat HaHayal, Tel Aviv, with branches in the U.S. and Germany and a distributor network in several European countries. The device is in use in two Israeli hospitals (Sheba and Hadassah Ein Kerem) and enjoys expanded reimbursement coverage in 260 German hospitals. Laminate has 18 employees and aims to reduce fistula failure, re-interventions, and the cost burden of vascular access complications. Laminate Medical Technologies, founded in 2012, develops VasQ, a blood vessel support device implanted in patients with kidney failure who require dialysis. VasQ is already in use in hospitals in Europe and Israel, including leading centers in the UK, Switzerland, Italy and Germany. The device is intended to reduce the high failure rate of fistula surgery and the need for repeat operations. Laminate is completing US clinical trials and pursuing FDA approval while expanding its activities in the European market. To support these efforts the company is expanding its experienced medical‑device staff and opening a US branch. Financially, Laminate raised $8 million in the current Series B and has raised $13 million to date.

Led · Series D · Feb 2016

Regentis Biomaterials develops cartilage repair solutions, with offices in Princeton, New Jersey and Or Akiva, Israel. Its core product, GelrinC, is a proprietary hydrogel invented at the Technion that is implanted as a liquid and cured in‑situ to form a resorbable implant gradually replaced by regenerated cartilage. Earlier trials in Europe and Israel showed GelrinC provided patients relief from knee pain and improved function to return to normal activities. The company closed a $15M Series D led by Haisco Pharmaceutical Group and intends to use the proceeds to conduct a pivotal clinical trial of GelrinC in the United States aimed at obtaining FDA marketing approval. As part of the investment, Haisco will serve as GelrinC's exclusive distributor in China. Regentis is led by CEO Alastair Clemow, Ph.D., and counts Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and Technion funds among its investors. Regentis Biomaterials develops GelrinC, a biodegradable implant intended to enhance growth of articular cartilage in damaged knee joints. The company is based in Or Akiva, Israel and Princeton, NJ and is led by CEO and President Dr. Alastair Clemow. GelrinC is currently an investigational device; prior pre-clinical studies demonstrated its ability to regrow cartilage. Regentis is conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of GelrinC. The company intends to use the new funding to expand clinical efforts for the implant. GelrinC is not available for sale in the U.S., Europe or Israel while clinical evaluation is ongoing.

Led · Series C · Jul 2015

MST develops image‑guided surgical systems built on a proprietary image analytic technology platform; its flagship product is AutoLap®, an FDA‑cleared and CE‑approved image‑guided laparoscope positioning system. AutoLap® offers surgeons hands‑free, natural control of laparoscopic procedures with minimal user interaction and is aimed at the large minimally invasive surgery market. The company says healthcare providers benefit from cost‑effective technology that can enable more efficient procedures. MST is privately held, was founded in 2005, and is based in Yokneam, Israel. Management plans to use the recent investment primarily to expand marketing and sales of AutoLap® in the U.S., Europe and China. As part of the deal, the lead investor Haisco will serve as AutoLap®’s exclusive distributor in China.